Events and Presentations

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events and Presentations

Presentations and Posters
Date Title Format
Sep 10, 2022
ESMO Congress 2022: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC)
Aug 11, 2022
Current Corporate Presentation
May 26, 2022
ASCO 2022: Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
Apr 12, 2022
AACR 2022: Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
Mar 07, 2022
ESMO TAT Virtual Congress 2022: Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Oct 07, 2021
AACR-NCI-EORTC – Virtual International Conference: Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers
Sep 18, 2021
ESMO Congress 2021: Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)
Jun 04, 2021
2021 ASCO Annual Meeting: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations
Apr 10, 2021
Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations
Mar 05, 2021
38th Annual Miami Breast Cancer Conference: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)
Mar 02, 2021
ESMO TAT Virtual Congress 2021: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Upcoming Event
More events are coming soon.